Here are eight updates on GI companies from the past week.
Allegan, Forest Laboratories and Ironwood Pharmaceuticals accused Sandoz of patent infringement in a recent suit to prevent Sandoz from bringing a generic version of Linzess to market.
The FDA approved Advanced Accelerator Applications' Lutathera, a radioactive drug intended for the treatment of gastroenteropancreatic neuroendocrine tumors. This is the first time a radiopharmaceutical has been approved for the treatment of GEP-NETs.
Olympus added a new product to its EndoTherapy portfolio when it became the exclusive distributor of Intelligent Endoscopy's SmartBand Multi-Band Ligation Kit.
Innovate Biopharmaceuticals completed its reverse merger with Monster Digital, entirely absorbing the company and becoming a publicly traded entity.
Exalenz Bioscience's BreathID breath test platform can accurately detect clinically significant portal hypertension in non-alcoholic steatohepatitis patients with compensated advanced chronic liver disease.
The FDA approved Synergy Pharmaceuticals' irritable bowel syndrome with constipation treatment Trulance.